Takeaway

• According to a preplanned interim analysis of the MIRAGE trial in 749 patients with newly diagnosed glioblastoma, the addition of the proteasome inhibitor marizomib to standard of care (SOC) therapy neither improves overall survival (OS) nor progression-free survival (PFS).

Why this matters

• Postoperative SOC for patients with newly diagnosed glioblastomas is radiotherapy...